5:00 pm - 8:00 pmOpening Reception: The JOBS Act and its impact on Wall Street In the mist of cocktails and hors d'oeuvres, a panel of experts will provide concise analysis on the most significant developments: General Solicitation Rules and how companies can solicit investors; the emergence of Private Secondary Markets filling the void left by the dying IPO market; and the use of CrowdFunding websites, enabling companies to aggregate thousands of small investors. These presentations will be followed by a Keynote address from former NASDAQ Vice Chair David Weild IV, whose basic research into the structural flaws in the US Capital markets provided the foundation for the legislation.
July 12, 2012
7:00 am - 5:00 pmRegistration Desk Open
8:00 am - 12:20 pmPublic & Private Company Presentations
8:30 am - 9:30 amRegenerative Medicine PanelIn the political arena, the issue of regenerative medicine and ‘stem cells’ is an emotive and volatile debate. In the medical field, however, there is less question as to the ‘why’, and instead, a focus on the ‘how’ and ‘when’. The perfection and subsequent implementation of replacing damaged, lost or aging tissues and organs through replacement or autologous stimulation will have profound effects on the ceiling of modern medicine and treatment.
9:45 am - 10:45 amOncology PanelDespite the myriad of information and analysis on the subject of cancer treatment, there still remain several promising opportunities considered ‘alternative’ to the general public. Brachytherapy, for example, is an appealing emerging technology to investors, physicians and patients as a safer and more targeted alternative to chemotherapy. The field of cancer immunotherapy and vaccination is also on the cusp of a paradigm shift, with several integral technological advancements soon reaching the public.
11:00 am - 12:00 pmBiotechnology PanelThis session will provide an overview of the big developments in primary areas of biotechnology investing, including regenerative medicine, neurological disorders, pharmaceogenetics, vaccines and infectious diseases.
12:30 pm - 1:30 pmNetworking Luncheon
1:30 pm - 5:00 pmPublic & Private Company Presentations
1:30 pm - 2:30 pmMedical Devices PanelThe medical device space possesses two inherent qualities that investors value: stability, and disruptive technology. On the one hand, there is what is often perceived as a less daunting regulatory guidance process, as well as a stable framework for sales models, predictable revenue streams, international efforts and infrastructure. On the other hand, it is one of the few spaces in which disruptive technology can have an immediate impact. Further, there exists the opportunity to cross-pollinate, as medical device companies can enter healthcare, the consumer market and the technology space.
2:45 pm - 3:45 pmDiagnostics PanelAs technology evolves, molecular and diagnostic tests are becoming more convenient, quicker, cheaper and more available closer to or at the point of care (POC). The convergence between understanding the genome, developing biomarkers for certain diseases and technology is already accelerating the growth of (and interest in) this space. The ability to treat a patient faster and more effectively will cut out so much excess cost in the system, and the concept of personalized medicine will lead to better prognosis and ultimately greater quality of life.
4:00 pm - 5:00 pmHealth Information PanelThis panel will focus on the technological developments in physician-patient communication. Commercial and professional technology is shifting toward cloud-based computing, but what does that mean for the medical industry, which is not yet in the final stages of going paperless? How can physicians communicate more effectively to take more control of their healthcare? How can the technological boom fix what many experts describe as a broken system?
5:00 pm - 7:00 pmReception: sponsored by Greater Zurich Area AGA European themed reception.
